What is Dogwood Therapeutics, Inc.?
, a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 39.57M, and a P/E ratio of 0.1x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.